New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;PFE;DUF;CG;HLF;CALM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
February 26, 2015
19:28 EDTHLFHerbalife reverses, now down 1.3% after earnings conference call
Subscribe for More Information
19:28 EDTHLFHerbalife results negatively impacted by declines in U.S., Mexico, Brazil, Korea
19:25 EDTHLFHerbalife CEO Johnson says 'not happy with topline results'
Subscribe for More Information
16:22 EDTHLFHerbalife up 6% following Q4 results, guidance
16:21 EDTHLFHerbalife CEO comments on 2015 outlook
Michael Johnson, chairman and CEO stated, “2014 was a record year in terms of net sales, volume and sales leader retention. It was also a year of transition, as we continue to implement changes that we believe will create a stronger company with the ideal combination of growth and sustainability. We have seen the success of these changes in early adopter markets and remain confident that our other markets will follow a similar pattern through 2015 and beyond.” Johnson continued, "Our revised guidance reflects the currency landscape faced by all global companies and the short-term volume impact of the enhancements we are making. We believe we are executing the right long-term strategy and are confident in our ability to create sustainable value for our shareholders and the millions of Herbalife members and their customers worldwide."
16:20 EDTHLFHerbalife sees FY15 free cash flow $430M-$460M
Subscribe for More Information
16:20 EDTHLFHerbalife sees FY15 CapEx $120M-$140M
16:19 EDTHLFHerbalife sees FY15 volume point growth (4.5%)-(1.5%) y/y
Subscribe for More Information
16:19 EDTHLFHerbalife sees Q1 volume point growth (8%)-(5%) y/y
Subscribe for More Information
16:18 EDTHLFHerbalife sees FY15 currency adjusted adjusted EPS $5.30-$5.70, consensus $5.08
Sees FY15 currency adjusted net sales growth (1%)-2%, consensus $4.8B.
16:17 EDTHLFHerbalife sees Q1 currency adjusted EPS $1.30-$1.40, consensus $1.30
Sees Q1 currency adjusted net sales growth (7.5%)-(4.5%), consensus $1.17B.
16:15 EDTHLFHerbalife sees FY15 adjusted EPS $4.10-$4.50, consensus $5.08
Subscribe for More Information
16:14 EDTHLFHerbalife reports Q4 adjusted EPS $1.41, consensus $1.22
Reports Q4 revenue $1.1B, consensus $1.16B.
15:30 EDTHLFNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Monster Beverage (MNST), consensus 59c... Ross Stores (ROST), consensus $1.11... Gap (GPS), consensus 74c... Autodesk (ADSK), consensus 24c... Universal Health Services (UHS), consensus $1.50... Southwestern Energy (SWN), consensus 50c... Ensco (ESV), consensus $1.36... J.C. Penney (JCP), consensus 11c... Nimble Storage (NMBL), consensus (14c)... Herbalife (HLF), consensus $1.22... Allscripts Healthcare (MDRX), consensus 9c... SBA Communications (SBAC), consensus 2c... Aruba Networks (ARUN), consensus 27c... Splunk (SPLK), consensus 4c... Air Lease (AL), consensus 61c... Ingram Micro (IM), consensus 99c... Weight Watchers (WTW), consensus 7c... Northern Oil and Gas (NOG), consensus 19c... Envision Healthcare (EVHC), consensus 36c... Infoblox (BLOX), consensus 5c... Live Nation (LYV), consensus (41c)... OmniVision (OVTI), consensus 29c... Bonanza Creek Energy (BCEI), consensus 27c.
15:23 EDTBMYBristol-Myers reports ALLY trial demonstrates 97% hepatitis C cure rates
Subscribe for More Information
13:30 EDTHLFEarnings Preview: Herbalife reporting after Soros, Post Holdings increase stakes
Subscribe for More Information
12:31 EDTPFEPfizer says CDC recommends serogroup B meningococcal vaccine for those at risk
Subscribe for More Information
08:35 EDTBMYBristol-Myers says BMS-966176 Phase IIa study met primary endpoint
Subscribe for More Information
06:11 EDTHLFStocks with implied volatility above IV index mean; ANF HLF
Stocks with implied volatility above IV index mean; Abercrombie & Fitch (ANF) 64, Herbalife (HLF) 94 according to iVolatility.
February 25, 2015
08:36 EDTBMYBristol-Myers announces data from Phase IIb BMS-663068 trial
Bristol-Myers Squibb Company announced data from a Phase IIb trial of investigational compound BMS-663068, designed as an HIV-1 attachment inhibitor, in treatment-experienced HIV-1 patients. In the study, which compared BMS-663068 to a pharmacoenhanced protease inhibitor, virologic response rates and immunologic reconstitution were similar across the BMS-663068 and Reyataz/ritonavir arms of the trial through 48 weeks. Specifically, 61-82% of BMS-663068 patients had HIV-1 RNA levels <50 c/mL, compared to 71% of Reyataz/ritonavir patients at week 48. HIV-1 RNA levels <50 c/mL typically indicate virus replication is undetectable. Treatment with BMS-663068 resulted in no dose response safety signals, no treatment discontinuations related to adverse events, and no treatment-related serious adverse events over the course of the trial. The most common AEs were headache and abdominal pain. Due to the positive results seen thus far, a Phase III clinical trial of the attachment inhibitor among heavily treatment-experienced patients began on Monday, February 23, 2015. For the purposes of the Phase III trial, heavily treatment-experienced patients are defined as individuals who can no longer formulate a viable regimen due to accumulation of drug resistance, past intolerabilities or antiretroviral contraindications. The Phase IIb study results, presented yesterday at the 22nd Conference on Retroviruses and Opportunistic Infections, highlight the novel mechanism of action of the investigational prodrug BMS-663068, which when converted into its active moiety BMS-626529, is designed to bind directly to the HIV gp120 protein, and prevents initial viral attachment to the host CD4+ T cell and entry into the host immune cell.
05:53 EDTHLFStocks with implied volatility above IV index mean; ANF HLF
Subscribe for More Information
February 24, 2015
15:07 EDTCGCarlyle, Cap Gemini talks to buy CSC have 'fizzled,' Reuters says
Consulting company Cap Gemini and private equity firm Carlyle Group (CG) previously held talks about a potential acquisition of Computer Sciences Corp. (CSC), though the talks have since "fizzled," reported Reuters, citing people familiar with the matter. CSC is now working with Royal Bank of Canada (RY) to review its options, the report added. Reference Link
14:56 EDTCGCarlyle, Cap Gemini talks to buy CSC have 'fizzled,' Reuters says
Subscribe for More Information
13:45 EDTHLFHerbalife February volatility elevated into Q4 and outlook
Herbalife February weekly option implied volatility is at 166, March is at 99, April is at 88, May is at 84; compared to its 26-week average of 65 according to Track Data, suggesting large near term price movement into the expected release of Q4 results on February 26.
10:48 EDTHLFHerbalife critics seek meetings with Icahn, Soros, NY Post reports
Subscribe for More Information
08:07 EDTPFEPfizer announces Trumenba studies met primary objectives
Subscribe for More Information
07:46 EDTBMYJacobs Engineering awarded contract from Bristol-Myers
Jacobs Engineering Group (JEC) announced that it received a contract from Bristol-Myers Squibb Company (BMY) to provide architectural and engineering services for a new large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland. The facility is being designed to produce multiple therapies for the company’s robust and growing portfolio of approved and investigational biologic medicines, and to increase Bristol-Myers Squibb’s biologics manufacturing capacity. The new facility is expected to include multiple large scale bioreactors, a purification area, as well as office and laboratory space. Bristol-Myers Squibb’s Board of Directors has approved initial funding that will support the first phase of the project, with the full cost of the facility expected to be finalized in the second half of 2015. The facility is estimated to be operational in 2019.
05:44 EDTHLFStocks with implied volatility above IV index mean; ANF HLF
Subscribe for More Information
February 23, 2015
13:49 EDTCGCarlyle Group, Advent mull sale of H.C. Starck, Bloomberg reports
Subscribe for More Information
12:21 EDTBMYOn The Fly: Midday Wrap
Subscribe for More Information
08:15 EDTBMYRigel Pharmaceuticals and Bristol-Myers announces R&D collaboration agreement
Rigel Pharmaceuticals (RIGL) and Bristol-Myers (BMY) announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors. TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body. The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune system's activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Bristol-Myers Squibb's Opdivo and Yervoy. Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize small molecule therapeutics derived from Rigel's TGF beta library, including, but not limited to, those approved to treat cancer. Bristol-Myers Squibb will pay $30M upfront and Rigel will be eligible to receive development and regulatory milestones that could total more than $309M for a successful compound approved in multiple indications. Rigel will also be eligible to receive tiered royalties on the net sales of any products from the collaboration.
08:06 EDTBMYBristol-Myers, Rigel enter R&D agreement for TGF beta receptor kinase inhibitors
Rigel Pharmaceuticals (RIGL) and Bristol-Myers Squibb (BMY) announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel’s extensive portfolio of small molecule TGF beta receptor kinase inhibitors. TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body. The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune system’s activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Bristol-Myers Squibb’s Opdivo, or nivolumab, and Yervoy, or ipilimumab. Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize small molecule therapeutics derived from Rigel’s TGF beta library, including, but not limited to, those approved to treat cancer. Bristol-Myers Squibb will pay $30M upfront and Rigel will be eligible to receive development and regulatory milestones that could total more than $309M for a successful compound approved in multiple indications. Rigel will also be eligible to receive tiered royalties on the net sales of any products from the collaboration.
08:01 EDTBMYBristol-Myers to acquire Flexus, potential total consideration may be $1.25B
Subscribe for More Information
06:09 EDTHLFStocks with implied volatility above IV index mean; ANF HLF
Subscribe for More Information
February 20, 2015
14:04 EDTHLFHerbalife February volatility elevated into Q4 and outlook
Subscribe for More Information
10:33 EDTPFEBattleground update: AbbVie named top global pick at Jefferies
Subscribe for More Information
10:31 EDTPFEPfizer announces FDA acceptance of NDA for Rapamune
Pfizer announced that the FDA has accepted for priority review a supplemental New Drug Application for RAPAMUNE for the treatment of lymphangioleiomyomatosis, a rare, progressive lung disease in women of childbearing age that is often fatal. With the Priority Review designation for the sNDA, Pfizer anticipates a decision in June of 2015 based on the anticipated Prescription Drug User Fee Act action date. The sNDA is based on results from the Multicenter International Lymphangioleiomyomatosis Efficacy and Safety of Sirolimus Trial. The MILES Trial included 89 LAM patients with moderate lung impairment who were randomized to receive RAPAMUNE or placebo for 12 months, followed by a 12 month observation period. In the trial, those treated with RAPAMUNE for one year experienced stabilization of lung function as measured by forced expiratory volume in one second.
07:23 EDTBMY, PFEAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
05:13 EDTHLFStocks with implied volatility above IV index mean; HLF ARCP
Subscribe for More Information
February 19, 2015
18:25 EDTPFEPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
14:49 EDTPFEWalgreens selected by Pfizer as one of pharmacies to dispense Ibrance
Subscribe for More Information
07:12 EDTPFEWharton Health Care Club to hold a conference
Subscribe for More Information
05:31 EDTHLFStocks with implied volatility above IV index mean; HLF ANF
Subscribe for More Information
February 18, 2015
10:05 EDTCGOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Agnico Eagle (AEM) upgraded to Overweight from Neutral at JPMorgan... Amarin (AMRN) upgraded to Buy from Neutral at SunTrust... Capital Product (CPLP) upgraded to Accumulate from Neutral at Global Hunter... Carlyle Group (CG) upgraded to Buy from Neutral at Citigroup... Danone (DANOY) upgraded to Neutral from Underperform at Exane BNP Paribas... Express (EXPR) upgraded on lower promotional activity at Piper Jaffray... Kforce (KFRC) upgraded to Outperform from Market Perform at Avondale... Legg Mason (LM) upgraded to Buy from Hold at Jefferies... Rackspace (RAX) upgraded following Q4 results at Pacific Crest... Rosetta Resources (ROSE) upgraded to Buy from Neutral at Global Hunter... SeaChange (SEAC) upgraded to Buy from Hold at Noble Financial... Valero (VLO) upgraded to Outperform from Neutral at Credit Suisse... Veeco (VECO) upgraded to Buy from Hold at Noble Financial... Wolverine World Wide (WWW) upgraded to Neutral from Underperform at Sterne Agee.
06:08 EDTCGCarlyle Group upgraded to Buy from Neutral at Citigroup
Citigroup upgraded Carlyle Group to Buy saying it believes the company is entering a "robust" harvesting cycle. Citi says Carlyle is at a favorable inflection point and raised its price target for the stock to $32 from $30.50.
February 17, 2015
17:02 EDTHLFSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
15:36 EDTPFETianyin JCM plans for FDA certification process
Tianyin Pharmaceutical (TPI) updated on the business and development at its Jiangchuan Macrolide Facility, or JCM, active pharmaceutical ingredients operation. In addition to JCM's certification at India, along with other international clients located at Bangladesh, Philippines and Iran on import status, TPI plans for FDA certification process at its JCM facility in order to service international clients such as Pfizer's (PFE) and their subsidiaries in China, the company said. "This is expected to translate to further demand for JCM's macrolide API business in both the domestic and international markets," Tianyin stated.
11:49 EDTHLFSoros increased Herbalife stake last quarter amid slide, Bloomberg says
George Soros’ Soros Fund Management increased its stake in Herbalife during the fourth quarter as the stock declined, according to Bloomberg, citing two people familiar with the matter who noted that the firm will disclose details in a filing as early as today. The Fly notes that large investors are given until today by the SEC to disclose their 13F filings outlining their holdings as of the end of the fourth quarter of 2014. Reference Link
11:18 EDTHLFHong Kong women posed as Herbalife presidents, South China Morning Post says
Two women who claimed to be presidents of Herbalife took HK$50M in orders for the company's products from about 60 people before disappearing, according to The South China Morning Post. A number of the victims lost a significant amount of money on the scheme, the newspaper stated. Reference Link
10:01 EDTPFECVS says PCSK9 inhibitors could cost system $150B annually
Subscribe for More Information
09:22 EDTHLFFormer Herbalife distributors to reject $15M settlement, NY Post reports
Subscribe for More Information
February 13, 2015
14:03 EDTBMYBristol-Myers DMD treatment granted orphan status
Subscribe for More Information
13:10 EDTHLFAckman: 'Shocked' if something with Herbalife, regulators doesn't happen in 2015
Pershing Square's Bill Ackman is speaking on Fox Business News.
10:28 EDTPFEPfizer announces FDA acceptance for review of NDA for ALO-02
Subscribe for More Information
09:21 EDTCGOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Cytokinetics (CYTK), up 15.6%... King Digital (KING), up 22.2%... Cyberark Software (CYBR), up 19.2%... Web.com (WWWW), up 4%... CBS (CBS), up 3.4%. ALSO HIGHER: Freescale Semiconductor (FSL), up 10.9% following a New York Post report that the company is exploring a sale. Carlyle Group (CG), which owns Freescale, along with Blackstone (BX), is up 1.5%. Blackstone is up fractionally... Whiting Petroleum (WLL), up 4.4% following a Bloomberg report that the company is seeking a buyer for assets in North Dakota... Ariad Pharmaceuticals (ARIA), up 5.7% following a CNBC report that Sarissa Capital is seeking to replace Ariad CEO and Chairman Harvey Berger. DOWN AFTER EARNINGS: Knowles (KN), down 20.3%... Zynga (ZNGA). down 12.4%... J.M. Smucker (SJM), down 2.1%. ALSO LOWER: Magnachip Semiconductor (MX), down 51.7% after restating financial results... Idera Pharmaceuticals (IDRA), down 7.6% after 20M share Secondary priced at $3.75.
08:19 EDTPFE, BMYAckman noncommittal on McDonald's rumors, Bloomberg reports
Subscribe for More Information
07:10 EDTCGFreescale said to be exploring a sale, NY Post reports
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use